Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23160740 | 1.00 | SF3B3 (0.77) | SF3B3HMGCR | |
| SCHEMBL31571155 | 1.00 | SF3B3 (0.77) | SF3B3HMGCR | |
| SCHEMBL12877545 | 1.00 | SF3B3 (0.77) | SF3B3HMGCR | |
| SCHEMBL31204556 | 1.00 | SF3B3 (0.77) | SF3B3HMGCR | |
| SCHEMBL23160741 | 1.00 | SF3B3 (0.77) | SF3B3HMGCR | |
| SCHEMBL23160742 | 1.00 | SF3B3 (0.77) | SF3B3HMGCR | |
| SCHEMBL12877326 | 1.00 | SF3B3 (0.77) | SF3B3HMGCR | |
| SCHEMBL1267885 | 0.95 | SF3B3 (0.71) | SF3B3HMGCR | |
| SCHEMBL16716722 | 0.95 | SF3B3 (0.69) | SF3B3HMGCR | |
| SCHEMBL12877547 | 0.94 | SF3B3 (0.70) | SF3B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062404-A1 | METHOD FOR PRODUCING MACROLIDE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2026-03-05 | — | — | US | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4570796-A1 | METHOD FOR PRODUCING MACROLIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2025-06-18 | — | — | EP | claimed |
| CN-119948022-A | Process for producing macrolide compounds | 卫材R&D管理有限公司 | 2025-05-06 | — | — | CN | claimed |
| WO-2024239281-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | claimed |
| WO-2024240173-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | claimed |
| EP-4426727-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | Hangzhou Dac Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | claimed |
| EP-4426729-A1 | SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE | Hangzhou Dac Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | claimed |
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | claimed |
| WO-2023078273-A1 | SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-05-11 | — | — | WO | claimed |
| CN-116096752-A | anti-BCMA antibody-drug conjugates and methods of use thereof | 卫材R&D管理有限公司 | 2023-05-09 | — | — | CN | claimed |
| EP-4161966-A1 | ANTI-BCMA ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2023-04-12 | — | — | EP | claimed |
| EP-4149483-A2 | COMPOSITIONS AND METHODS FOR ENHANCING CANCER IMMUNOTHERAPY | Fred Hutchinson Cancer Center (US) | 2023-03-22 | — | — | EP | claimed |
| WO-2022078524-A4 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-12-08 | — | — | WO | claimed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | claimed |
| US-7655442-B2 | Efficiently producing a macrolide compound, in which a cyclodextrin is made to be present in a culture broth of actinomycetes; antitumor agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-02 | — | — | US | claimed |
| US-20070155696-A1 | Method for stabilizing macrolide compounds | MERCIAN CORPORATION (JP) | 2007-07-05 | — | — | US | claimed |
| EP-1710244-A1 | METHOD OF STABILIZING MACROLIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2006-10-11 | — | — | EP | claimed |
| US-7026352-B1 | Physiologically active substances | MERCIAN CORPORATION (JP) | 2006-04-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155696-A1 | Method for stabilizing macrolide compounds | MRPL21, ERG28, RPN1 | SF3B3 2845/4885HMGCR 173/4885 |
| US-20260062404-A1 | METHOD FOR PRODUCING MACROLIDE COMPOUND | CYP51A1, LAS1L, MRPL21 | SF3B3 781/4885HMGCR 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.